Editorial Commentary
The future of EGFR exon 20 targeting in non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
28
.
(25 June 2024)
Editorial Commentary
Is atezolizumab plus bevacizumab with chemotherapy effective for non-small cell lung cancer with EGFR- or ALK-alteration?
AME Clinical Trials Review
2024;
2:
27
.
(25 June 2024)
Editorial Commentary
ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
AME Clinical Trials Review
2024;
2:
26
.
(25 April 2024)
Editorial Commentary
Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?
AME Clinical Trials Review
2024;
2:
25
.
(25 April 2024)
Editorial Commentary
Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC)
AME Clinical Trials Review
2024;
2:
24
.
(25 April 2024)
Editorial Commentary
New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients
AME Clinical Trials Review
2024;
2:
23
.
(25 April 2024)
Editorial Commentary
Confirmatory surgical exploration of the mediastinum after negative endobronchial ultrasound-guided transbronchial needle aspiration: which method and when to perform it, if needed
AME Clinical Trials Review
2024;
2:
22
.
(25 April 2024)
Editorial Commentary
Neoadjuvant osimertinib: a promising therapeutic option for locally advanced EGFR-mutant lung adenocarcinoma
AME Clinical Trials Review
2024;
2:
21
.
(25 April 2024)
Editorial Commentary
Chest tube after lung resection—a small change to a great benefit
AME Clinical Trials Review
2024;
2:
20
.
(25 April 2024)
Editorial Commentary
How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?
AME Clinical Trials Review
2024;
2:
19
.
(25 April 2024)
Editorial Commentary
Genomic and molecular considerations for sotorasib treatment in KRAS G12C-mutant non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
18
.
(25 April 2024)
Editorial Commentary
Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
17
.
(25 April 2024)
Editorial Commentary
Breaking barriers: bridging the gap in lung cancer trials through inclusive representation
AME Clinical Trials Review
2024;
2:
16
.
(25 April 2024)
Editorial Commentary
Optimizing the role of immunotherapy in the management of resectable non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
15
.
(25 April 2024)
Editorial Commentary
The ELUCIDATE trial: a step closer to complete resection of lung tumors
AME Clinical Trials Review
2024;
2:
14
.
(25 April 2024)
Editorial Commentary
NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?
AME Clinical Trials Review
2024;
2:
13
.
(25 April 2024)
Editorial Commentary
Combination metronomic chemotherapy and immunotherapy in non-small cell lung cancer remains exploratory: the VinMetAtezo trial
AME Clinical Trials Review
2024;
2:
12
.
(25 April 2024)
Editorial Commentary
Immunotherapy as first-line treatment in locally advanced/metastatic and previously untreated squamous cell lung cancer: which advances?
AME Clinical Trials Review
2024;
2:
11
.
(25 April 2024)
Editorial Commentary
Combining neoadjuvant and adjuvant immunotherapy breathes more life into the growing body of lung cancer treatment paradigms
AME Clinical Trials Review
2024;
2:
10
.
(25 February 2024)
Editorial Commentary
The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC
AME Clinical Trials Review
2024;
2:
9
.
(25 February 2024)
Editorial Commentary
Commentary: is segmentectomy curative in patients with early-stage ground glass opacity predominant non-small cell lung cancer?
AME Clinical Trials Review
2024;
2:
8
.
(25 February 2024)
Editorial Commentary
Changing the way we treat KRAS G12C non-small cell lung cancers
AME Clinical Trials Review
2024;
2:
7
.
(25 February 2024)
Editorial Commentary
How should we combine radiotherapy and immunotherapy in advanced non-small cell lung cancer?
AME Clinical Trials Review
2024;
2:
6
.
(25 February 2024)
Editorial Commentary
The role of confirmatory mediastinoscopy after negative endosonography: is it truly necessary?
AME Clinical Trials Review
2024;
2:
5
.
(25 February 2024)
Editorial Commentary
A long-awaited novel approach for the treatment of undetectable small-sized lung cancers in thoracoscopic surgery
AME Clinical Trials Review
2024;
2:
4
.
(25 February 2024)
Editorial Commentary
Real-world evidence for immune checkpoint inhibitors in extensive-stage small cell lung cancer
AME Clinical Trials Review
2024;
2:
3
.
(25 February 2024)
Editorial Commentary
CheckMate 817: expanding the pool of patients eligible for immune checkpoint inhibitor therapy in advanced non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
2
.
(25 February 2024)
Editorial Commentary
Should we change strategy for adjuvant therapy according to surgery type in stage II–IIIA non-small cell lung cancer?
AME Clinical Trials Review
2024;
2:
1
.
(25 February 2024)
Editorial Commentary
Two-year analysis of CodeBreaK 100 phase I/II trial: achieved goals of an ongoing challenge
AME Clinical Trials Review
2023;
1:
20
.
(25 December 2023)
Editorial Commentary
What is the most optimal postoperative chest tube placement method after lung resection?
AME Clinical Trials Review
2023;
1:
19
.
(25 December 2023)